Direct-to-Consumer Pharmacogenomic Testing
Enrollment options
This online, self-paced, text-based module educates healthcare professionals towards a better understanding of the benefits and limitations of direct-to-consumer pharmacogenomic testing, when to pursue confirmatory clinical testing, and how to interpret pharmacogenomic test results using evidence-based resources.
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and click 'continue' to enroll (it's free!).
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series: Course Directors
Roseann S. Donnelly (Gammal), PharmD, BCPS
Associate Professor
Massachusetts College of Pharmacy and Health Sciences
Additional Content Reviewers
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:- Differentiate between the delivery models for pharmacogenomic testing.
- Identify the benefits and limitations of direct-to-consumer (DTC) pharmacogenomic testing.
- Interpret DTC pharmacogenomic test results.
- Evaluate the clinical actionability of genetic variants detected by a DTC pharmacogenomic test using evidence-based resources.
- Determine when confirmatory clinical testing is needed when faced with DTC pharmacogenomic test results.
- Explain why confirmatory clinical pharmacogenomic test results may differ from direct-to-consumer pharmacogenomic test results for the same patient.
- Discuss issues related to documenting DTC pharmacogenomic test results in the electronic health record.